Navigation Links
Watson Announces Actos(R) Patent Challenge Settlement
Date:3/10/2010

MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.  Under terms of the agreement, Takeda granted Watson a non-exclusive royalty free license to its U.S. patents covering Actos®. Under the terms of the agreement, Watson is permitted to launch its generic equivalent version of Actos® on August 17, 2012, or earlier under certain circumstances. 

Actos® had approximately $3.4 billion in brand sales for the twelve months ending December 31, 2009, according to IMS Health. Actos® is a once-daily oral prescription medication that, with diet and exercise, has been shown to be effective for the treatment of type 2 diabetes.

Actos® is a registered trademark of Takeda Chemical Industries, Ltd.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions, if any; availability and pricing of third-party-sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third-party manufacturers' facilities, products, and/or businesses; the impact of competitive products and pricing, market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2009.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Filing of Generic Opana(R) ER Application
2. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
3. Watson to Present at CLSA/Asia USA Investors Forum
4. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
5. Watson Completes Acquisition of Eden Biodesign
6. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
7. Watson Files FDA Application for Generic Rozerem(R)
8. Watson to Present at Credit Suisse Healthcare Conference
9. Watson and Barr Settle Lawsuit Over Oxytrol(R)
10. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
11. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... May 2, 2016 Kalorama Information noted the ... Records) market in a recent white paper.  The healthcare ... physician usage, a growing market are among the top ... Kalorama,s report EMR 2016: The Market for ... seventh complete study of the EMR industry, and the ...
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... is launching a new client service center in La Vergne, Tennessee, near Nashville. ... provide the full range of Empyrean client services. , “Our Nashville-area center allows ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from ... the United States and account for one death every four minutes. Many people ... disabled. HCR ManorCare is launching a video series called “Your Brain,” in conjunction with ...
(Date:5/3/2016)... Indianapolis, IN (PRWEB) , ... May 03, 2016 ... ... employee benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition ... powerhouse Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo ... solutions and digital consulting services to the federal government, has been awarded a ... / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive ...
(Date:5/3/2016)... ... May 03, 2016 , ... AvePoint, ... release of DocAve 6 Service Pack (SP) 7, the enterprise-class infrastructure ... 2016 and take advantage of the platform’s latest features – whether in an ...
Breaking Medicine News(10 mins):